KR20220107001A - Pnag 포함 미생물에 대한 연속 치료를 제공하는 방법 - Google Patents

Pnag 포함 미생물에 대한 연속 치료를 제공하는 방법 Download PDF

Info

Publication number
KR20220107001A
KR20220107001A KR1020227021201A KR20227021201A KR20220107001A KR 20220107001 A KR20220107001 A KR 20220107001A KR 1020227021201 A KR1020227021201 A KR 1020227021201A KR 20227021201 A KR20227021201 A KR 20227021201A KR 20220107001 A KR20220107001 A KR 20220107001A
Authority
KR
South Korea
Prior art keywords
vaccine
charged
formula
reactor
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227021201A
Other languages
English (en)
Korean (ko)
Inventor
마이클 와이언드
제럴드 에프. 스위스
Original Assignee
알로펙스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 알로펙스, 인크. filed Critical 알로펙스, 인크.
Publication of KR20220107001A publication Critical patent/KR20220107001A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020227021201A 2019-11-22 2020-11-20 Pnag 포함 미생물에 대한 연속 치료를 제공하는 방법 Pending KR20220107001A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962939331P 2019-11-22 2019-11-22
US62/939,331 2019-11-22
US202062994130P 2020-03-24 2020-03-24
US62/994,130 2020-03-24
PCT/US2020/061594 WO2021102320A1 (en) 2019-11-22 2020-11-20 Methods for providing continuous therapy against pnag comprising microbes

Publications (1)

Publication Number Publication Date
KR20220107001A true KR20220107001A (ko) 2022-08-01

Family

ID=75980043

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227021201A Pending KR20220107001A (ko) 2019-11-22 2020-11-20 Pnag 포함 미생물에 대한 연속 치료를 제공하는 방법

Country Status (11)

Country Link
US (1) US20230053458A1 (enExample)
EP (1) EP4061411A4 (enExample)
JP (2) JP2023502276A (enExample)
KR (1) KR20220107001A (enExample)
CN (1) CN114845731A (enExample)
AU (1) AU2020386971A1 (enExample)
BR (1) BR112022009924A2 (enExample)
CA (1) CA3162238A1 (enExample)
IL (1) IL293091A (enExample)
WO (1) WO2021102320A1 (enExample)
ZA (1) ZA202205546B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3152520A1 (en) * 2019-08-27 2021-03-04 OneBioPharma, Inc. Antimicrobial vaccine compositions
US11173199B2 (en) * 2019-11-13 2021-11-16 Alopexx Inc. Low contaminant compositions
WO2023173020A1 (en) * 2022-03-11 2023-09-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibody materials and methods targeting microbial polysaccharides

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2415358T3 (es) * 2004-04-21 2013-07-25 The Brigham And Women's Hospital, Inc. Péptidos de fijación a la poli-N-acetil glucosamina (PNAG/DPNAG) y procedimientos para el uso de los mismos
CN102159540B (zh) * 2008-07-21 2015-08-12 布赖汉姆妇女医院 与合成的β-1,6葡糖胺寡糖相关的方法和组合物
US20130116423A1 (en) * 2010-04-23 2013-05-09 A. Stewart Campbell Synthetic Oligosaccharides for Staphylococcus Vaccine
WO2012145626A1 (en) * 2011-04-22 2012-10-26 Ancora Pharmaceuticals Inc. Synthetic oligosaccharides for staphylococcus vaccine
US20150086601A1 (en) * 2012-05-07 2015-03-26 Sanofi Methods for preventing biofilm formation
MX2014013637A (es) * 2012-05-07 2015-02-05 Sanofi Sa Metodos para prevencion de la formacion de biopelicula.
RU2019101166A (ru) * 2012-05-30 2020-03-02 Дзе Брихэм Энд Уимен`З Хоспитал, Инк. Композиции полисахаридов и способы применения
US10828360B1 (en) * 2020-02-04 2020-11-10 OneBioPharma, Inc. Methods for inhibiting biofilm formation

Also Published As

Publication number Publication date
JP2026016535A (ja) 2026-02-03
BR112022009924A2 (pt) 2022-08-09
WO2021102320A1 (en) 2021-05-27
CN114845731A (zh) 2022-08-02
JP2023502276A (ja) 2023-01-23
ZA202205546B (en) 2023-05-31
US20230053458A1 (en) 2023-02-23
CA3162238A1 (en) 2021-05-27
EP4061411A1 (en) 2022-09-28
IL293091A (en) 2022-07-01
EP4061411A4 (en) 2023-11-29
AU2020386971A1 (en) 2022-06-09

Similar Documents

Publication Publication Date Title
JP2026016535A (ja) Ｐｎａｇを含む微生物に対する持続的治療を提供するための方法
KR102713536B1 (ko) 클렙시엘라 뉴모니아에 대한 백신
CA2961694C (en) Vaccines against streptococcus pneumoniae serotype 8
CN105085349A (zh) 与合成的β-1,6葡糖胺寡糖相关的方法和组合物
KR20200106033A (ko) 클렙시엘라 뉴모니아에 대한 백신
US20210244808A1 (en) Methods for inhibiting biofilm formation
JP2026021461A (ja) 低汚染抗菌ワクチン
EP2012821A2 (en) Antibodies for the detection of bacillus anthracis and vaccine against b. anthracis infections
JP2025148346A (ja) 抗菌性ワクチン組成物
HK40077830A (en) Methods for providing continuous therapy against pnag comprising microbes
EP2911698B1 (en) Glycoconjugates and their use as potential vaccines against infection by shigella flexneri
HK40078447A (en) Low contaminant antimicrobial vaccines
HK40076154A (en) Antimicrobial vaccine compositions
TW202440156A (zh) 對抗克雷白氏肺炎菌之疫苗
CA2126341A1 (en) Lipid-a analogs: new monosaccharide and dissaccharide intermediates for eliciting therapeutic antibodies and for antitumor and antiviral activities

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000